Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 36856617

Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
N Engl J Med
Publication date
2023 Mar 2
First author
Patel SP

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Nat Rev Clin Oncol. 2023 May;20(5):284. doi: 10.1038/s41571-023-00752-3.
    note
    Source null
    related pmid
    36899061
    relationship
    Comment in
  2. citation
    Cancer. 2023 Jul 1;129(13):1952. doi: 10.1002/cncr.34884.
    note
    Source null
    related pmid
    37300812
    relationship
    Comment in

Authors and identifiers

  1. name
    Patel SP
    type
    Author
  2. name
    Othus M
    type
    Author
  3. name
    Chen Y
    type
    Author
  4. name
    Wright GP Jr
    type
    Author
  5. name
    Yost KJ
    type
    Author
  6. name
    Hyngstrom JR
    type
    Author
  7. name
    Hu-Lieskovan S
    type
    Author
  8. name
    Lao CD
    type
    Author
  9. name
    Fecher LA
    type
    Author
  10. name
    Truong TG
    type
    Author
  11. name
    Eisenstein JL
    type
    Author
  12. name
    Chandra S
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Patel SP
    type
    Author
  2. name
    Othus M
    type
    Author
  3. name
    Chen Y
    type
    Author
  4. name
    Wright GP Jr
    type
    Author
  5. name
    Yost KJ
    type
    Author
  6. name
    Hyngstrom JR
    type
    Author
  7. name
    Hu-Lieskovan S
    type
    Author
  8. name
    Lao CD
    type
    Author
  9. name
    Fecher LA
    type
    Author
  10. name
    Truong TG
    type
    Author
  11. name
    Eisenstein JL
    type
    Author
  12. name
    Chandra S
    type
    Author
bibliography ids
  1. nci-bib-f6ac74d4257fd4c40790786a
book metadata
content sha256
81cf12fecf023252b256aa10c1245e1ef39ff9d0581a11a83c7ae5f6d6e8b742
document type
citation
dois
  1. 10.1056/NEJMoa2211437
electronic publication date
display
Source null
precision
missing
year
Source null
evidence scope
bibliographic_metadata_only
id
pubmed:36856617
immutable id
pubmed:36856617@81cf12fecf023252b256aa10c1245e1ef39ff9d0581a11a83c7ae5f6d6e8b742
journal
abbreviation
N Engl J Med
issn electronic
1533-4406
issn print
0028-4793
issue
9
name
The New England journal of medicine
nlm unique id
0255562
pages
813-823
volume
388
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Nat Rev Clin Oncol. 2023 May;20(5):284. doi: 10.1038/s41571-023-00752-3.
    note
    Source null
    related pmid
    36899061
    relationship
    Comment in
  2. citation
    Cancer. 2023 Jul 1;129(13):1952. doi: 10.1002/cncr.34884.
    note
    Source null
    related pmid
    37300812
    relationship
    Comment in
outcomes validated
false
pmid
36856617
provenance
batch id
d370e99271168e8a8a13
provider
NCBI PubMed ESummary
record sha256
9a203ad6be2f7771fb660151bb002fac98d3eb930f7f533cf0497ff468046a76
response sha256
f65ace3ceb1efa86f3fbab8e01ce265243e7c6b7f13c5f71c357c1f219ad79c4
retrieved at
2026-09-09T23:48:13.005737+00:00
publication date
display
2023 Mar 2
precision
day
year
2023
publication types
  1. Clinical Trial, Phase II
  2. Comparative Study
  3. Journal Article
  4. Randomized Controlled Trial
  5. Research Support, U.S. Gov't, P.H.S.
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/36856617/
title
Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma.

Preserved source evidence · Not medical advice